Human Trafficking Network Busted in Delhi-NCR; Over 30 Children Sold

A groundbreaking study published in Nature on February 5, 2025, reveals that a personalized mRNA vaccine shows significant potential in treating late-stage kidney cancer. Conducted by researchers at Dana-Farber Cancer Institute in Boston, the phase one clinical trial involved nine patients with stage III and IV renal cell carcinoma, all of whom remained cancer-free for a median of 40 months after surgery, according to the study.
The vaccine was tailored to each patient based on genetic mutations identified using artificial intelligence. Researchers injected the vaccine, designed against specific proteins produced by these mutations, to help the immune system target cancer cells. Dr. Satya Prakash Yadav from Medanta Hospital emphasized the importance of this study, highlighting its ability to attend to key driver mutations in patient tumors.
However, experts caution that while the results are promising, this treatment method may not be applicable for all types of cancer. Dr. Rajeev Jayadevan of the India Medical Association stressed the need for tempered expectations, stating, “We should not give false hope."